Harrington, Charles - University of Aberdeen - School of Medicine, Medical Sciences and Nutrition

个人简介

Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He continued with his PhD working with Dr Julia Douglas on the regulation of cell wall synthesis in yeast. This was followed by a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow. He spent four years studying the synthesis of cell wall polymers, this time those in bacteria. Dr Harrington then spent over two years in research and development at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface. In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology to develop diagnostic tests for Alzheimer’s disease. Working in the Cambridge Brain Bank Laboratory over a period of 10 years, he was supported by the Medical Research Council, ICI Ltd. and a Newton Trust Research Fellowship from Trinity College. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed a Senior Research Fellow in the Department of Mental Health. In 2002, research was translated to the clinic, with a phase 2 trial in Alzheimer's disease completed in 2008 and phase 3 trials starting in 2012. Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd.

研究领域

Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Gauthier, S., Feldman, HH., Schneider, LS., Wilcock, GK., Frisoni, GB., Hardlund, JH., Moebius, HJ., Bentham, P., Kook, KA., Wischik, DJ., Schelter, BO., Davis, CS., Staff, RT., Bracoud, L., Shamsi, K., Storey, JMD., Harrington, CR. & Wischik, CM. (2016). 'Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial'. The Lancet, vol 388, no. 10062, pp. 2873-2884. DOI: [ONLINE] DOI: 10.1016/S0140-6736(16)31275-2 ?imi?, G., Leko, MB., Wray, S., Harrington, CR., Delalle, I., Jovanov-Milo?evi?, N., Ba?adona, D., Buée, L., Silva, RD., Giovanni, GD., Wischik, CM. & Hof, PR. 'Monoaminergic Neuropathology in Alzheimer's disease'. Progress in Neurobiology. DOI: [ONLINE] DOI: 10.1016/J.PNEUROBIO.2016.04.001 Lai, RYK., Harrington, CR. & Wischik, CM. (2016). 'Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease'. Biomolecules, vol 6, no. 2, 19. DOI: [ONLINE] DOI: 10.3390/BIOM6020019 [ONLINE] AURA: BIOMOLECULES_06_00019_V2.PDF Melis, V., Magbagbeolu, M., Rickard, JE., Horsley, D., Davidson, K., Harrington, KA., Goatman, K., Goatman, EA., Deiana, S., Close, SP., Zabke, C., Stamer, K., Dietze, S., Schwab, K., Storey, JMD., Harrington, CR., Wischik, CM., Theuring, F. & Riedel, G. (2015). 'Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models'. Behavioural Pharmacology, vol 26, no. 4, pp. 353-368. DOI: [ONLINE] DOI: 10.1097/FBP.0000000000000133 [ONLINE] AURA: EFFECTS_OF_OXIDIZED_AND_REDUCED_FORMS_OF.4.PDF Melis, V., Zabke, C., Stamer, K., Magbagbeolu, M., Schwab, K., Marshall, P., Weh, RW., Bachmann, S., Deiana, S., Moreau, PH., Davidson, K., Harrington, KA., Rickard, JE., Horsley, D., Garman, R., Mazurkiewicz, M., Niewiadomska, G., Wischik, CM., Harrington, CR., Riedel, G. & Theuring, F. (2015). 'Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration'. Cellular and Molecular Life Sciences, vol 72, no. 11, pp. 2199-2222. DOI: [ONLINE] DOI: 10.1007/S00018-014-1804-Z [ONLINE] AURA: ART_3A10.1007_2FS00018_014_1804_Z.PDF Harrington, CR., Storey, JMD., Clunas, S., Harrington, KA., Horsley, D., Ishaq, A., Kemp, SJ., Larch, CP., Marshall, C., Nicoll, SL., Rickard, JE., Simpson, M., Sinclair, JP., Storey, LJ. & Wischik, CM. (2015). 'Cellular Models of Aggregation-Dependent Template-Directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer's Disease'. The Journal of Biological Chemistry, vol 290, no. 17, pp. 10862-10875. DOI: [ONLINE] DOI: 10.1074/JBC.M114.616029 [ONLINE] AURA: J._BIOL._CHEM._2015_HARRINGTON_10862_75.PDF Flores-Rodríguez, P., Ontiveros-Torres, MA., Cárdenas-Aguayo, MC., Luna-Arias, JP., Meraz-Ríos, MA., Viramontes-Pintos, A., Harrington, CR., Wischik, CM., Mena, R., Florán-Gardu?o, B. & Luna-Mu?oz, J. (2015). 'The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease'. Frontiers in Neuroscience, vol 9, 33. DOI: [ONLINE] DOI: 10.3389/FNINS.2015.00033 [ONLINE] AURA: FNINS_09_00033.PDF Baddeley, TC., McCaffrey, J., Storey, JMD., Cheung, JKS., Melis, V., Horsley, D., Harrington, CR. & Wischik, CM. (2015). 'Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease'. Journal of Pharmacology and Experimental Therapeutics, vol 352, no. 1, pp. 110-118. DOI:[ONLINE] DOI: 10.1124/JPET.114.219352 Wischik, CM., Staff, RT., Wischik, DJ., Bentham, P., Murray, AD., Storey, JMD., Kook, KA. & Harrington, CR. (2015). 'Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease'. Journal of Alzheimer's Disease, vol 44, no. 2, pp. 705-720. DOI: [ONLINE] DOI: 10.3233/JAD-142874 [ONLINE] AURA: FULLTEXT.PDF Wischik, CM., Harrington, CR. & Storey, JMD. (2014). 'Tau-aggregation inhibitor therapy for Alzheimer's disease'. Biochemical Pharmacology, vol 88, no. 4, pp. 529-539. DOI: [ONLINE] DOI: 10.1016/J.BCP.2013.12.008 [ONLINE] AURA: 1_S2.0_S0006295213007612_MAIN.PDF